EyePoint Pharmaceuticals Reports Results for EYP-1901 in P-II Trial for the Treatment of Wet Age-Related Macular Degeneration
Shots:
- The P-II (DAVIO 2) trial evaluates EYP-1901 vs aflibercept control in patients (n=160) with wet AMD previously treated with an SoC anti-VEGF therapy. The 1EP was change in BCVA & 2EPs were safety, change in CST & patients free of supplemental anti-VEGF injections
- The results depicted that in the sub-group of supplement-free patients for up to 6mos., the change in BCVA was superior vs control & the results were consistent & durable in a range of wet AMD patient types
- Additionally, the 2nd presentation highlighted the previously reported results from the P-II (DAVIO 2) trial that met its 1EPs with both doses depicting statistical non-inferiority change in BCVA vs control & 85% mean reduction in historical treatment burden
Ref: EyePoint Pharmaceuticals | Image: EyePoint Pharmaceuticals
Related News:- Alimera Acquires Rights from EyePoint Pharmaceuticals to Commercialise Yutiq in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
